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Introduction
Mitochondrial disorders are a phenotypically diverse group of diseases caused by genetic defects that impair oxidative phosphorylation (OXPHOS). Cytochrome c oxidase (COX, complex IV), the terminal component of the mitochondrial electron transport chain (ETC), catalyses the reduction of molecular oxygen to water and helps establish the proton gradient across the inner mitochondrial membrane required for ATP synthesis. The catalytic core of COX is composed of three subunits (COX I-III), encoded by the mitochondrial genome (MT-CO1-3), and their prosthetic groups. COX I, II and III are surrounded by 11 nuclear-encoded subunits, many of which are expressed as tissue-specific isoforms, that are suggested to perform an insulating or regulatory role 1 . Assembly of the COX holoenzyme is a complex module-based process that occurs around COX I-III 2 .
Over 50 pathogenic mutations, including 14 truncating mutations, are reported in MT- and are associated with a broad clinical spectrum of disease that includes sideroblastic anaemia, sensorineural deafness, intractable epilepsy, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), and mitochondrial myopathy (MitoMap 3 ).
Here we report a patient with adult-onset Leigh syndrome in whom the previously unreported stop codon mutation m.6579G>A in MT-CO1 was detected. We also review the phenotypic spectrum associated with MT-CO1 truncating mutations and discuss the potential mechanisms that contribute towards their clinical heterogeneity.
Patient and Methods

Clinical case
A 28 year old female presented aged 17 years with a subacute encephalopathy, preceded by a viral gastrointestinal illness, associated with diplopia, dizziness, dysarthria, and hearing loss.
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Cranial nerve examination revealed abnormal eye movements, bilateral lower motor neuron facial weakness, and bulbar dysfunction. There were extrapyramidal and pyramidal signs in the limbs with no evidence of cerebellar or sensory disturbance. She recovered fully after the acute phase of the illness but subsequently developed a transient unilateral facial weakness and persistent fatigue. Past medical history included a possible seizure and episode of confusion following a childhood vaccination. A maternal uncle had epilepsy but there was no other family history of neurological, neuromuscular or multisystem disease ( Figure 1A ).
Laboratory tests at initial presentation, including blood lactate, ammonia, CPK, ESR, HIV, Lyme serology, copper and caeruloplasmin, ASO titres, amino acids, ANA, ANCA, anticardiolipin and anti-basal ganglia antibodies, and urinary organic and amino acids were normal. CSF was acellular, glucose was normal and oligoclonal bands were negative.
However, CSF protein and lactate levels were raised (0.45g/L, reference range 0.17-0.36g/L and 3.06mmol/L, reference range 0.8-1.9mmol/L respectively).
Cerebral MRI initially showed high T2 signal intensities in the basal ganglia bilaterally, predominantly affecting the putamen and globus pallidus, without gadolinium enhancement.
Repeat cerebral MRI brain 10 weeks after the acute phase of the illness confirmed resolution of the acute changes ( Figure 1B and C ). An EEG demonstrated a resolving encephalopathy.
Nerve conduction studies revealed a mild generalised polyneuropathy with demyelinating features, while EMG was normal.
Skeletal muscle histochemical, biochemical and molecular genetic studies
Muscle biopsy of the vastus lateralis was performed following informed consent aged 18
years. Standard muscle section staining was undertaken, including COX and modified
Gomori trichrome. Mitochondrial respiratory chain enzyme activities were measured by spectrophotometric analysis. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and in-gel activity staining of complex IV was completed using muscle homogenate [4] [5] [6] . The entire mitochondrial genome, extracted from muscle tissue, was sequenced as previously described 7 .
Results
Histochemical analysis of muscle tissue revealed several COX deficient fibres (Figure 2A ), but no ragged red fibres. There was a relative reduction of complex IV activity compared with complex I and complexes II+III activities ( Figure 2B and C). Protein levels of mitochondrial respiratory chain complexes and complex IV in-gel activity in muscle tissue was comparable with controls (Supplementary Figure 1) .
Sequencing of the entire mitochondrial genome revealed the novel truncating mitochondrial DNA (mtDNA) mutation m.6579G>A; p.Gly226X predicted to result in a premature stop codon in MT-CO1. The mutation was present at 70% mutant load in muscle tissue compared with 40% mutant load in blood, with no detectable mutant mtDNA in maternal blood ( Figure   1A ). The variant is not reported in Genbank (45,494 full length and 69,730 short control region containing sequences 3 , and occurs within a residue which is highly conserved across different species 8 . Residual muscle tissue was unavailable for single fibre mtDNA heteroplasmy studies or measurement of the relative abundance of mtDNA encoded COX subunits.
Discussion
We report the novel stop codon mutation in MT-CO1 causing adult-onset Leigh syndrome.
The diagnostic criteria for Leigh syndrome include a progressive neurological disease with
developmental delay, basal ganglia involvement (clinically and on imaging studies and/or neuropathological examination), and elevated blood or CSF lactate caused by genetically mediated mitochondrial dysfunction 9, 10 . Adult-onset Leigh syndrome is a rare but wellrecognised presentation of mitochondrial disease, frequently associated with COX deficiency 11 and typically caused by mtDNA mutations 10 .
The m.6579G>A; p.Gly226X variant is highly likely to be pathogenic. A similar encephalomyopathic phenotype caused by a truncating MT-CO1 mutation has previously been described 12 . The m.6579G nucleotide is highly conserved and the premature stop codon introduced by the mutation is predicted to result in loss of more than half of the total polypeptide. The mutation is heteroplasmic, with higher mutant levels in muscle than blood, typical for pathogenic mtDNA mutations, and it segregates with disease with no mutant MT-CO1 detectable in the unaffected mother's blood. Histochemical and biochemical analyses of muscle tissue were consistent with impaired COX function. Finally, the mutation is absent from control samples.
Seven, primarily de novo, truncating mutations in MT-CO1 are reported ( Table 1) . The clinical spectrum is varied and includes anaemia, myopathy, rhabdomyolysis, and central neurological or multisystem disease phenotypes. The patient described in this report presented with adult-onset Leigh syndrome. The relatively mild histochemical and biochemical COX deficiency detected in the patient's skeletal muscle tissue is consistent with the late onset presentation and clinically undetectable muscle weakness. A low normal, rather than reduced, complex IV activity in the muscle tissue of patients with pathogenic MT-CO3 mutations is reported with CNS phenotypes 13 , and a more severe enzymatic defect would be expected in brain tissue. Interestingly, the muscle heteroplasmy levels in our patient are similar to previously reported cases. This potentially reflects the influence nuclear genetic ACCEPTED MANUSCRIPT 
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